HUE066879T2 - A Kv3-csatornák modulátorai a fájdalom kezelésére - Google Patents

A Kv3-csatornák modulátorai a fájdalom kezelésére

Info

Publication number
HUE066879T2
HUE066879T2 HUE16813020A HUE16813020A HUE066879T2 HU E066879 T2 HUE066879 T2 HU E066879T2 HU E16813020 A HUE16813020 A HU E16813020A HU E16813020 A HUE16813020 A HU E16813020A HU E066879 T2 HUE066879 T2 HU E066879T2
Authority
HU
Hungary
Prior art keywords
modulators
channels
treat pain
pain
treat
Prior art date
Application number
HUE16813020A
Other languages
English (en)
Hungarian (hu)
Inventor
Charles Large
Giuseppe Alvaro
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of HUE066879T2 publication Critical patent/HUE066879T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
HUE16813020A 2015-12-10 2016-12-09 A Kv3-csatornák modulátorai a fájdalom kezelésére HUE066879T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses

Publications (1)

Publication Number Publication Date
HUE066879T2 true HUE066879T2 (hu) 2024-09-28

Family

ID=55274489

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16813020A HUE066879T2 (hu) 2015-12-10 2016-12-09 A Kv3-csatornák modulátorai a fájdalom kezelésére

Country Status (20)

Country Link
US (3) US11147813B2 (OSRAM)
EP (1) EP3386506B1 (OSRAM)
JP (3) JP7149847B2 (OSRAM)
KR (1) KR102812887B1 (OSRAM)
CN (2) CN108472288B (OSRAM)
AU (1) AU2016367239B2 (OSRAM)
BR (1) BR112018011700B1 (OSRAM)
DK (1) DK3386506T3 (OSRAM)
EA (1) EA038059B1 (OSRAM)
ES (1) ES2974902T3 (OSRAM)
FI (1) FI3386506T3 (OSRAM)
GB (1) GB201521751D0 (OSRAM)
HR (1) HRP20240497T1 (OSRAM)
HU (1) HUE066879T2 (OSRAM)
IL (1) IL259717B (OSRAM)
MX (1) MX385578B (OSRAM)
PL (1) PL3386506T3 (OSRAM)
PT (1) PT3386506T (OSRAM)
SG (1) SG11201804123VA (OSRAM)
WO (1) WO2017098254A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
KR102854594B1 (ko) 2018-10-16 2025-09-02 오티포니 세라피틱스 리미티드 신규한 화합물
TW202031645A (zh) * 2018-10-30 2020-09-01 丹麥商H 朗德貝克公司 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
NZ775496A (en) 2018-11-30 2026-01-30 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
MX2022009702A (es) 2020-02-06 2022-09-07 Autifony Therapeutics Ltd Moduladores de kv3.
MX2024001899A (es) 2021-08-10 2024-03-01 Autifony Therapeutics Ltd Moduladores del canal de potasio.
CN113788741B (zh) * 2021-09-28 2023-12-29 大连九信精细化工有限公司 一种制备2-环丙基苯酚衍生物的方法
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001855A1 (ru) 2008-06-06 2011-08-30 Юсб Фарма, С.А. Соединения, содержащие циклобутоксигруппу
PL2509961T3 (pl) * 2009-12-11 2016-09-30 Pochodne imidazolidynodionu
ES2560304T3 (es) * 2010-12-06 2016-02-18 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
CN103974944B (zh) * 2011-12-06 2016-11-02 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
EP2852588B8 (en) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013175215A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
IL259717B (en) 2021-05-31
US11944623B2 (en) 2024-04-02
HRP20240497T1 (hr) 2024-08-16
EP3386506B1 (en) 2024-01-24
EA201891377A1 (ru) 2019-01-31
EP3386506A1 (en) 2018-10-17
CN108472288B (zh) 2024-05-28
EA038059B1 (ru) 2021-06-30
BR112018011700A2 (pt) 2018-11-27
AU2016367239B2 (en) 2020-07-09
WO2017098254A1 (en) 2017-06-15
PL3386506T3 (pl) 2024-06-03
CN108472288A (zh) 2018-08-31
MX2018007074A (es) 2018-12-12
JP7149847B2 (ja) 2022-10-07
GB201521751D0 (en) 2016-01-27
SG11201804123VA (en) 2018-06-28
BR112018011700B1 (pt) 2023-12-26
US11147813B2 (en) 2021-10-19
PT3386506T (pt) 2024-03-28
DK3386506T3 (da) 2024-05-06
CA3005302A1 (en) 2017-06-15
JP2022141699A (ja) 2022-09-29
US20190000848A1 (en) 2019-01-03
ES2974902T3 (es) 2024-07-02
MX385578B (es) 2025-03-18
US20220071998A1 (en) 2022-03-10
JP2025003958A (ja) 2025-01-14
US20250017925A1 (en) 2025-01-16
KR102812887B1 (ko) 2025-05-26
FI3386506T3 (fi) 2024-04-23
JP2019506367A (ja) 2019-03-07
AU2016367239A1 (en) 2018-06-07
IL259717A (en) 2018-07-31
CN118267386A (zh) 2024-07-02
KR20180097549A (ko) 2018-08-31

Similar Documents

Publication Publication Date Title
IL259717B (en) modulators of kv3 channels for pain management
ZA201802663B (en) Modulators of kras expression
IL259421B (en) ror - gamma modulators
IL242564A0 (en) Sodium channel modulators for pain management
IL258779B (en) Modulators of sestrin-gator2 interaction and their uses
ZA201702410B (en) Sodium channel modulators for the treatment of pain and diabetes
IL259762B (en) Complement activity modulators
PL3964213T3 (pl) Leczenie zaburzeń zachowania
ZA201805861B (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
SI3250230T1 (sl) Modulatorji aktivnosti komplementa
ZA201705847B (en) Treatment of pain
EP3271017A4 (en) Treatment of skin conditions
EP3288616A4 (en) Reducing pain of skin piercing using vibration
GB201518002D0 (en) Ketamine for the treatment of somatoform pain disorder
HK40006632A (en) Treatment of pain
AU2016901912A0 (en) Treatment of Pain
AU2015900943A0 (en) Treatment of skin conditions
GB201418268D0 (en) Composition & methods of treatment